reports
Collegium to Report First Quarter 2025 Financial Results on May 8, 202...
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025 STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q1 2025 Earnings Call.” An audio webcast will...
Collegium to Participate in 24th Annual Needham Virtual Healthcare Con...
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025. Details of the event are as follows:Fireside Chat Date and Time: Tuesday, April 8, 2025, at 9:30 a.m. ET The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website ...
Collegium to Present Real-World Data at PainConnect 2025, the American...
Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American Academy of Pain Medicine (AAPM)’s Annual Meeting, being held in Austin, TX, from April 3-6, 2025. Among these, the poster titled “Route of Administration and Other Clinical Outcomes Among Exposures to Buprenorphine Pain Medications and Schedule II Opioids” h...
Collegium Pharmaceutical Inc: 2 directors
Two Directors at Collegium Pharmaceutical Inc sold 28,410 shares at between 30.025USD and 30.027USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...
Collegium Announces Updates to its Board of Directors and Executive Le...
Collegium Announces Updates to its Board of Directors and Executive Leadership Team – Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives Appointed to Leadership Team; David Dieter, as Executive Vice President, General Counsel Jane Gonnerman as Executive Vice President, Strategy and Corporate Development and Dean J. Patras, as Chief People Officer – STOUGHTON, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL)...
Collegium Announces Poster Presentations at the 2025 National Associat...
Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will have two poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) at the National Association of Pediatric Nurse Practitioners (NAPNAP) 46th National Conference on ...
Collegium to Participate in Upcoming Investor Conferences
Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conferences: Leerink Partners 2025 Global Healthcare ConferenceTuesday, March 11, 2025 Jefferies Biotech on the Beach SummitWednesday, March 12, 2025 Barclays 27th Annual Global Healthcare ConferenceThursday, March 13, 2025 About Collegium Pharmaceutical, Inc.Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of p...
Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial R...
Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results – Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $12.5 Million and $69.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $107.7 Million and $401.2 Million – – Ended 2024 with Cash, Cash Equivalents and Marketable Securities of $162.8 Million;...
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Result...
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025 STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the market closes on Thursday, February 27, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q4 ...
Collegium Appoints Nancy S. Lurker to its Board of Directors
Collegium Appoints Nancy S. Lurker to its Board of Directors STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. “Collegium is pleased to welcome Nancy to our Board of Directors,” said Mike Heffernan, Founder and Chairman of the Board of Collegium. “Nancy’s expertise in driving commercial growth and strategic acquisitions will be of great value to Collegium as we continue to build a leading, diversified biopharmaceutical company committed...
Collegium Provides 2025 Financial Guidance and Business Update
Collegium Provides 2025 Financial Guidance and Business Update – Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million – – Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million – STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update. “In 2024, we executed on our prio...
Collegium to Participate in Upcoming Investor Conferences
Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in the following investor conferences: Jefferies London Healthcare ConferenceFireside Chat Date and Time: Tuesday, November 19, 2024, at 1:30 p.m. GMT Piper Sandler 36th Annual Healthcare ConferenceFireside Chat Date and Time: Thursday, December 5, 2024, at 1:00 p.m. ET The fi...
Collegium Reports Record Third Quarter 2024 Financial Results
Collegium Reports Record Third Quarter 2024 Financial Results – Generated Record Q3’24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca® Revenue of $53.2 Million and Record Xtampza® ER Revenue of $49.5 Million – – Achieved Q3’24 GAAP Net Income of $9.3 Million – – Delivered Record Q3’24 Adjusted EBITDA of $105.1 Million, Up 18% Year-over-Year – – Closed Acquisition of Ironshore Therapeutics, Establishing Presence in Neurology (ADHD) – – Appointed Vikram Karnani as Chief Executive Officer of Collegium – – Conference Call Scheduled for Today at 4:30 p.m. ET ...
Collegium Appoints Vikram Karnani as Chief Executive Officer
Collegium Appoints Vikram Karnani as Chief Executive Officer Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical Businesses STOUGHTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that Vikram Karnani has been appointed as President and Chief Executive Officer (CEO) of Collegium and will join its Board of Directors effective November 12, 2024. Michael Heffernan, who has...
Collegium to Report Third Quarter 2024 Financial Results on November 7...
Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024 STOUGHTON, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please ...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
OCUL OCULAR THERAPEUTIX
HNRG HALLADOR ENERGY CO.
EAT BRINKER INTERNATIONAL INC.
DECK DECKERS OUTDOOR CORPORATION
CSIQ CANADIAN SOLAR INC.
COLL COLLEGIUM PHARMACEUTICAL INC.
CALM CAL-MAINE FOODS INC.
CAKE CHEESECAKE FACTORY INCORPORATED
BBW BUILD-A-BEAR WORKSHOP
ASPN ASPEN AEROGELS
APOG APOGEE ENTERPRISES INC.
AMSC AMERICAN SUPERCONDUCTOR CORP.
ALB ALBEMARLE CORPORATION
AAOI APPLIED OPTOELECTRONICS INC.
COF CAPITAL ONE FINANCIAL CORPORATION
ZUMZ ZUMIEZ INC.
VFC V.F. CORPORATION
CRVS CORVUS PHARMACEUTICALS
DESP DESPEGAR.COM CORP.
FNKO FUNKO CLASS A
AMD ADVANCED MICRO DEVICES INC.
ACMR ACM RESEARCH
PPIH PERMA PIPE INTERNATIONAL HOLDINGS
GLOB GAZIT-GLOBE LTD.
PLMR PALOMAR HOLDINGS
CAPR CAPRICOR THERAPEUTICS
CRMD CORMEDIX INC.
BILL BILL.COM HOLDINGS
ADPT ADAPTIVE BIOTECHNOLOGIES
GII SPDR S&P GLOBAL INFRASTRUCTURE
TVTX TRAVERE THERAPEUTICS INC
VHI VALHI INC.
ALKT ALKAMI TECHNOLOGY INC
SOFI SOFI TECHNOLOGIES INC
EVGO EVGO INC
ENVX ENOVIX CORP
TSE TRINSEO PLC
ASTS AST SPACEMOBILE INC
PLL PIEDMONT LITHIUM INC
MLTX MOONLAKE IMMUNOTHERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
RDW REDWIRE CORP
COYA COYA THERAPEUTICS INC
SKWD SKYWARD SPECIALTY INS GROUP INC
MLYS MINERALYS THERAPEUTICS INC
ELVN IMARA INC
WGS GENEDX HOLDINGS CORP.
KGS KODIAK GAS SERVICES INC
BYRN BYRNA TECHNOLOGIES INC
NMRA NEUMORA THERAPEUTICS INC
ATGL ALPHA TECHNOLOGY GROUP LTD
NGNE NEUROGENE INC
DAVE DAVE INC
LENZ LENZ THERAPEUTICS INC
IBTA IBOTTA INC
FIP FTAI INFRASTRUCTURE INC
CLMT CALUMET INC
NUTX NUTEX HEALTH INC
DOGZ DOGNESS INTERNATIONAL CORP
TECX TD GLOBAL TECHNOLOGY LEADERS CAD HEDGED INDEX ETF
TBNK TD CANADIAN BANK DIVIDEND INDEX ETF
RDDT REDDIT INC
Collegium Completes Acquisition of Ironshore Therapeutics
Collegium Completes Acquisition of Ironshore Therapeutics – Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD) – – Collegium Updates 2024 Financial Guidance to Reflect Expected Immediate Accretion from the Ironshore Acquisition – – 2024 Product Revenues, Net Expected in the Range of $620.0 Million to $635.0 Million – STOUGHTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it ...
Collegium to Participate in H.C. Wainwright 26th Annual Global Investm...
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference STOUGHTON, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference being held in New York, NY from September 9-11, 2024. Details of the event are as follows:Fireside Chat Date and Time: Monday, September 9, 2024, at 12:30 p.m. ET T...
Collegium Announces Eight Poster Presentations at PAINWeek Conference ...
Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024 STOUGHTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that eight poster presentations highlighting data regarding its diversified pain portfolio will be presented at PAINWeek Conference 2024, being held in Las Vegas, NV, from September 3–6, 2024. “Collegium is proud to present new real-world data at PAINWeek 2024 as part of our commitment to lea...
Collegium Reports Second Quarter 2024 Financial Results
Collegium Reports Second Quarter 2024 Financial Results – Generated Q2’24 Net Revenue of $145.3 Million and Record Belbuca® Revenue of $52.2 Million, Up 7% and 21% Year-over-Year, Respectively – – Achieved Q2’24 GAAP Net Income of $19.6 Million, Up 51% Year-over-Year – – Delivered Q2’24 Adjusted EBITDA of $96.0 Million, Up 12% Year-over-Year – – On Track to Close Acquisition of Ironshore Therapeutics in Q3’24, Adding Commercial Product Jornay PM® to Portfolio and Establishing Presence in Neurology (ADHD) – – Reaffirmed Full-Year 2024 Guidance for the Current Business – ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.